The Australian Government has appointed Emeritus Professor Ian Chubb AC, FAA FTSE to lead key reforms as Chair of the Inter-Governmental Policy Reform Group (IGPRG) for health and medical research, including clinical trials.
Minister for Health and Aged Care, The Hon Mark Butler MP commenting on the selection and appointment said, “Professor Chubb has dedicated his career to improving health and medical research and education in this county and I am pleased he has agreed to share his knowledge and experience through the IGPRG.”
All Australian health ministers agreed to establish the enduring IGPRG, which will provide policy and operational oversight of the National One Stop Shop for health and medical research.
Professor Chubb spoke with Australian Health Journal about his career as Chief Scientist for Australia, personal patient experience with a clinical trial and also the consultation done to date on clinical trial and medical research reform.
The National One Stop Shop Program will transform health and medical research in Australia, by making it easier for patients, researchers and sponsors to find, conduct and participate in clinical trials and research.
It will deliver innovative treatments and improved health outcomes, increase productivity and sustainability in the health system, create jobs and help grow Australia’s innovation economy.
Minister Butler attending the MedTech23 conference hosted by The Medical Technology Association of Australia in Sydney yesterday said,
“A One Stop Shop for cutting-edge clinical trials will ensure that Australian patients and researchers are among the first to benefit from new life-changing and life-saving medicines.
I have asked my department to work with states and territories on the next phase of analysis and platform specification as a priority.“
The IGPRG will also have a key role in implementing and regulating the National Clinical Trials Governance Framework which will ensure a nationally consistent approach to clinical trials.
He has been integral to the development of the One Stop Shop to date, having already led the national consultations on the design of the program.
Representing the medical technology industry MTAA CEO Ian Burgess supported the establishment of the IGPRG and the appointment of Chair Professor Chubb. He added, “There is an opportunity to maximise the potential of clinical trials in Australia by increasing the MedTech clinical trials beyond the 394 currently underway, through the One Stop Shop Program and work of the IGPRG.”
-
Strengthening Evidence Through Health Research Where Most People Access Healthcare
In February 2025, the Australian Government committed over $22 million for primary care research, including $5.2m awarded to Professor Michael Kidd, Director of the International Centre for Future Health Systems at UNSW and recently appointed Australia’s Chief Medical Officer, to lead the establishment of one of the largest research collaborations in Australia focused on improving primary care.
The Royal Australian College of GPs says a new national multidisciplinary consortium for primary care research is a positive step forward to improve patient care.
-
Calls for National Social Prescribing Scheme
The Royal Australian College of General Practitioners (RACGP), Consumers Health Forum of Australia (CHF) and Mental Health Australia are urging the government to implement a national social prescribing scheme to tackle Australia’s mental health and wellbeing crisis.
Mental ill health is a growing problem in Australia and has been made worse by the COVID-19 pandemic. Since 2017, GPs across Australia have rated mental health as the most common presentation they see as part of the RACGP’s annual Health of the Nation survey. Approximately 20% of patients consult their GP for what are primarily social problems.
-
Investigating use of dietary supplements for osteoarthritis
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
